In phase I or phase II clinical trials, PD-L1 blockage was especially efficient in relapsed/refractory B-cell non-Hodgkin’s lymphomas or in primary mediastinal large B-cell lymphoma. The gene discussed is CD274; the disease is B-cell non-Hodgkin lymphoma.